SEOUL — It was 7:30 a.m. on Christmas Eve when Cha Jung-hoon, South Korea’s deputy minister for small businesses, got a call from his boss to make an urgent three-hour car trip to visit syringe maker Poonglim Pharmatech.
The brief: work out how the government could convince and aid Poonglim, which had only about 80 employees, to rapidly scale up production of their low dead space (LDS) syringes, a type of syringe designed to minimize the amount of a drug left in the device after injection.
“It might help us get more vaccines,” Cha recalls then-minister Park Young-sun telling him.
Under fire in local media for not doing enough to secure COVID-19 vaccines, South Korea’s gove…
Keep on reading: How South Korea turbocharged specialty syringe production for COVID-19 jabs